메뉴 건너뛰기
The Lancet Oncology
Volumn 15, Issue 10, 2014, Pages 1040-1041
Cetuximab or bevacizumab in metastatic colorectal cancer?
Author keywords

[No Author keywords available]
Indexed keywords

BEVACIZUMAB; CETUXIMAB; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY;
EID: 84908602569     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70360-2     Document Type: Note
Times cited : (11)
References (9)
  • 1
    • 84908573757 scopus 로고    scopus 로고
    • FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
    • published online Aug 1.
    • Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014, published online Aug 1. http://dx.doi.org/10.1016/S1470-2045(14)70330-4.
    • (2014) Lancet Oncol
    • Heinemann, V.1    von Weikersthal, L.F.2    Decker, T.3
  • 2
    • 2142714017 scopus 로고    scopus 로고
    • Monoclonal antibodies as therapeutic agents for cancer
    • Harris M Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004, 5:292-302.
    • (2004) Lancet Oncol , vol.5 , pp. 292-302
    • Harris, M.1
  • 3
    • 84907023716 scopus 로고    scopus 로고
    • Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab
    • (abstr).
    • Ciardiello F, Lenz HJ, Kohne CH, et al. Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab. Proc Am Soc Clin Oncol 2014, 32(suppl):3506. (abstr).
    • (2014) Proc Am Soc Clin Oncol , vol.32 , pp. 3506
    • Ciardiello, F.1    Lenz, H.J.2    Kohne, C.H.3
  • 4
    • 61449202998 scopus 로고    scopus 로고
    • The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer
    • Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009, 14:22-28.
    • (2009) Oncologist , vol.14 , pp. 22-28
    • Hurwitz, H.I.1    Yi, J.2    Ince, W.3    Novotny, W.F.4    Rosen, O.5
  • 5
    • 84907027361 scopus 로고    scopus 로고
    • CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)
    • LBA3, (abstr).
    • Venook AP, Niedzwiecki D, Lenz HJ, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Proc Am Soc Clin Oncol 2014, 32(suppl):LBA3. (abstr).
    • (2014) Proc Am Soc Clin Oncol , vol.32
    • Venook, A.P.1    Niedzwiecki, D.2    Lenz, H.J.3
  • 6
    • 84883680951 scopus 로고    scopus 로고
    • Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
    • Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013, 369:1023-1034.
    • (2013) N Engl J Med , vol.369 , pp. 1023-1034
    • Douillard, J.Y.1    Oliner, K.S.2    Siena, S.3
  • 7
    • 84856717005 scopus 로고    scopus 로고
    • Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
    • Montagut C, Dalmases A, Bellosillo B, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012, 18:221-223.
    • (2012) Nat Med , vol.18 , pp. 221-223
    • Montagut, C.1    Dalmases, A.2    Bellosillo, B.3
  • 8
    • 84878862323 scopus 로고    scopus 로고
    • Amplification of the MET Receptor drives resistance to anti-EGFR therapies in colorectal cancer
    • Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET Receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013, 3:658-673.
    • (2013) Cancer Discov , vol.3 , pp. 658-673
    • Bardelli, A.1    Corso, S.2    Bertotti, A.3
  • 9
    • 84891629487 scopus 로고    scopus 로고
    • FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    • Loupakis F, Cremolini C, Salvatore L, et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014, 50:57-63.
    • (2014) Eur J Cancer , vol.50 , pp. 57-63
    • Loupakis, F.1    Cremolini, C.2    Salvatore, L.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.